Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology’s Divergent Thinkers

Gretchen Henkel  |  Issue: February 2008  |  February 1, 2008

If rheumatology organizations could be assigned human characteristics, OMERACT (which stands for Outcome Measures in Rheumatology, formerly Outcome Measures in Rheumatology Clinical Trials) would be the family’s divergent thinker. It has now been 16 years since the first international conference to achieve consensus about outcomes measures in rheumatology took place. Every two years since 1992, OMERACT has been providing an intellectual forum where an international community of clinicians, scientists, and regulatory, industry, and patient representatives sits down as equals to hammer out agreement on common endpoints to be used in clinical trials in the rheumatic diseases.

Like nurturing parents, OMERACT’s five executive committee members are justifiably proud, and even a bit amazed, at the way in which OMERACT’s unique organizational structure continues to build on its initial mission. Peter Brooks, MD, executive dean of health sciences at the University of Queensland in Brisbane, Australia, one of the original OMERACT founders and a current executive committee member, says, “Most organizations have to reinvent themselves after about a decade. But OMERACT doesn’t seem to have had to do that. It’s been 16 years and we’re still going strong and still expanding.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lee S. Simon, MD, associate clinical professor of medicine at Harvard Medical School in Boston and another executive committee member, says, “I’m involved in many other groups, and this has been the largest effort to be open of any group I’ve ever seen.”

TR talked recently with several of the founders and members of OMERACT to solicit their reflections on the organization’s purpose, accomplishments, and future opportunities and challenges.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
OMERACT Executive Committee members and spouses at a dinner held during the Malta conference. Clockwise from left: Rob Kew, OMERACT conference organizer; Mrs. Boers; Dr. Boers; Dr. Tugwell; Leanne Idzerda, OMERACT secretary; Dr. Brooks; Mrs. Tugwell; Dr. Simon; Jack Loftis, PhD; Dr. Strand.
OMERACT Executive Committee members and spouses at a dinner held during the Malta conference. Clockwise from left: Rob Kew, OMERACT conference organizer; Mrs. Boers; Dr. Boers; Dr. Tugwell; Leanne Idzerda, OMERACT secretary; Dr. Brooks; Mrs. Tugwell; Dr. Simon; Jack Loftis, PhD; Dr. Strand.

Why the Need?

For a specialty in which international collaborations and a focus on outcomes seem relatively common today, why would an initiative such as OMERACT be needed? In 1990, it was a different story. At that time, outcomes measurement was a huge challenge in clinical trials, says Vibeke Strand, MD, clinical professor of medicine in the division of immunology at Stanford University in Palo Alto, Calif., and another OMERACT executive committee member. Researchers in North America used different trial endpoints from their colleagues in Europe and regulatory agencies did not accept results of trials from countries other than their own.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Meeting ReportsPractice Support Tagged with:clinical trialsInternationalmeasuresOMERACTOutcome Measures in RheumatologyOutcomes

Related Articles

    Omeract How to Get into the “Act”

    April 1, 2010

    Meet this international organization that focuses on rheumatology outcome measures

    Patients Add Power to Research Initiatives

    October 7, 2011

    A look at how OMERACT involves people with rheumatic disease in its studies

    Patient-Centered Care Model for RA Flares Could Improve Self-Management of Symptoms

    December 16, 2015

    A recent trend to incorporate patient-reported outcomes (PROs) in clinical research, and ultimately clinical practice, is a response to the need to better measure and treat what patients truly care about, and adapt to the changing healthcare environment, which increasingly includes patient satisfaction as a key metric for overall quality of care, a metric tied…

    New Criteria for RA Remission

    February 12, 2011

    ACR and EULAR update 1981 criteria to reflect modern treatment options

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences